HCWB (HCW Biologics) Total Equity : $-9.97 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics Total Equity?

HCW Biologics's total equity for the quarter that ended in Sep. 2024 was $-9.97 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

HCW Biologics Total Equity Historical Data

The historical data trend for HCW Biologics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HCW Biologics Total Equity Chart

HCW Biologics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

9.00

14.40

51.19

37.43

13.46

HCW Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Equity	Get a 7-Day Free Trial															23.87	13.46	8.74	-6.30	-9.97

HCW Biologics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

HCW Biologics's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	28.514	-	15.052
	=	13.46

HCW Biologics's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity	=	Total Assets(Q: Sep. 2024 )	-	Total Liabilities(Q: Sep. 2024 )
	=	26.556	-	36.526
	=	-9.97

HCW Biologics Total Equity Related Terms

Thank you for viewing the detailed overview of HCW Biologics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

HCW Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 N Commerce Parkway, Miramar, FL, USA, 33025

Website

https://www.hcwbiologics.com

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Executives

Gary M Winer	director	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong	director, officer: Chief Executive Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam	officer: Chief Financial Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers	officer: SVP of Business Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene	director	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao	officer: VP of Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett	director	35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode	officer: See Remarks	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd.	10 percent owner	16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057